COVID testing reach HS1 Global provides the COVIBLOCK COVID-19 antibody test and hospital-grade PPE, with revenue from government funding for testing, indicating ongoing demand channels in healthcare settings and potential for expanded supply to clinics and hospitals.

North America focus Current operations are concentrated in North American markets, presenting upsell opportunities within U.S. and Canadian clinics and hospitals seeking reliable pricing and logistics for rapid diagnostics and PPE.

Affordable logistics ESCROW-insured shipping and 10-minute test results suggest a value proposition around fast, secure delivery and cash-flow predictability, which can be leveraged to win procurement contracts with federally funded programs.

Mid-size scale With 51-200 employees and revenue in the low-to-mid single digits, HS1 Global sits between startups and large integrators, offering a nimble, relationship-driven sales approach to mid-market healthcare providers.

Tech and credibility A lightweight tech stack and regulatory-backed product positioning position HS1 Global as a credible supplier for clinics and hospitals; targeting procurement teams that value compliance, security (reCAPTCHA), and measured performance could yield repeat orders.